Setrusumab (BPS804)
For the potential treatment of Osteogenesis Imperfecta (“OI”), a rare genetic bone condition affecting children and adults.
Our pipeline
This page is intended for Investors and Partners.
At Mereo, we unlock the potential of rare disease therapies that were not being progressed in pharmaceutical or biotechnology companies – creating new possibilities for all our stakeholders, from our investors to the patients that need us most.
We have already delivered five successful Phase 2 studies and a Phase 1b/2 ongoing. Our pipeline currently consists of six clinical-stage product candidates. Click below to see the relevant scientific publications for our products.
Core programs
Core programs
Partnered and Partnering Opportunities on Non-Core Programs
We have one additional program with current partnering opportunities. Navicixizumab has been licensed out to OncXerna and leflutrozole has been licensed to ReproNovo.
Navicixizumab (OMP305B83)
For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.
Acumapimod (BCT197)
For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
Leflutrozole (BGS649)
A novel once weekly oral aromatase inhibitor. Partnered with ReproNovo for further development.
Pipeline News
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
11 June 2024NOVATO, Calif. and LONDON, UK — June 11, 2024 — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study (NCT05125809) demonstrating that, as of a May 24, 2024 data cut-off date, treatment with setrusumab (UX143) continued to significantly reduce incidence of fractures in patients with OI with at least 14 months of follow-up. Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral density (BMD) at month 12 without evidence of plateau.
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
30 May 2024London, May 30, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST.
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27 March 2024London, March 27, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent corporate highlights.
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
08 January 2024LONDON, January 08, 2024 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its pipeline programs as well as an update on recent corporate developments.